1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Southern Cross Acquisition I Corp., a blank check company listed on Nasdaq under the ticker NCO, closed its initial public offering of 11,500,000 units at $10.00 per unit on July 22, 2026, for gross proceeds of $115,000,000, including the full exercise of the underwriters' over-allotment option. The company placed $115,000,000 in a trust account, which will not be released until a business combination is completed, shareholders redeem shares in certain circumstances, or the company fails to complete a business combination within 12 months of the IPO.
11,500,000 units sold at $10.00 per unit, for gross proceeds of $115,000,000, including 1,500,000 over-allotment units
Private sale of 239,300 units to the sponsor for $2,393,000, completed concurrently with the IPO closing
$115,000,000 placed in trust; funds are generally held until a business combination, or are returned if none is completed within 12 months of the IPO
Directors Zhiqiang Du, Zhuo Liang and Qian Xu became directors effective July 21, 2026; Ally Tong Zhang is chief executive officer
On July 23, 2026, JPMorgan Chase & Co. closed public offerings of four note series totaling $9.0 billion, comprising $6.0 billion of senior notes and $3.0 billion of subordinated notes. The notes were registered under a Form S-3 shelf registration, and the filing adds legal opinions on their legality, so the filing reports a financing event rather than a change in operating results.
Floating Rate Notes due 2030: $500 million aggregate principal amount
Southern California Edison and its SCE Recovery Funding LLC entered into an underwriting agreement on July 21, 2026 for $1,953,948,000 of Senior Secured Recovery Bonds, Series 2026-A, with the bonds expected to be dated July 28, 2026. The filing is a debt financing document; it does not report earnings or change guidance, and the filing does not state the use of proceeds beyond the issuance itself.
Underwriting agreement dated July 21, 2026 with RBC Capital Markets, Barclays Capital, Citigroup Global Markets and J.P. Morgan Securities as representatives
Bond principal of $1,953,948,000 under the Series 2026-A offering, issued by SCE Recovery Funding LLC
Bonds offered under a prospectus dated July 2, 2026; indenture, servicing and related agreements to be dated July 28, 2026
On July 23, 2026, Virtu Financial's subsidiaries signed Amendment No. 4 to their credit agreement, issuing $500 million of incremental senior secured first lien term B-2 loans. The total term B-2 loan balance is $2,029.55 million, and the company said the proceeds will be used for general corporate purposes. The filing adds to the company's debt, and it does not state how the loans will affect earnings.
Incremental term B-2 loans of $500 million were issued on July 23, 2026, with the total term B-2 balance at $2,029.55 million.
The loans mature on June 21, 2031, and amortize in annual installments of about 1.0% of the incremental principal.
Interest is set at either term SOFR plus 2.50%, or a base rate option plus 1.50%, at the borrower's election.
Per the press release, the loans were issued at par and the proceeds may be used for general corporate purposes.
Bone Biologics said it completed a July 2026 private placement with one healthcare-focused institutional investor, with gross proceeds of about $3.0 million before fees and expenses. The company says the financing extends its operating runway through Q2 2027, and the filing contains no revenue or earnings figures.
July 2026 private placement with a single healthcare-focused institutional investor, priced at-the-market under Nasdaq rules, for gross proceeds of about $3.0 million before fees and expenses
Series F and G warrants could add up to about $6.0 million if fully exercised for cash, but the company gives no assurance that any will be exercised
Company expects to complete patient enrollment in its first-in-human NB1 pilot study by year-end
Validated shelf life of rhNELL-1 extended to 29 months in May 2026, up from 24 months in December 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.